Neola Medical

Neola Medical is a Swedish medical technology company focused on developing Neola®, a noninvasive device for continuous lung monitoring in neonatal intensive care units. The company is organized around product development, clinical validation, and future commercialization, with operations centered in Lund, Sweden and a U.S. presence in Palo Alto.

— Neola Medical
%
Medical monitoring device70% Neola® hardware used for continuous lung monitoring in neonatal intensive care.
Disposable probes20% Single-use probes replaced daily for ongoing patient monitoring.
Clinical development and validation10% Clinical studies and regulatory work supporting market approval and launch.

Neola Medical sells to neonatal intensive care units, with a particular focus on hospitals that treat premature infants...

  • U.S. teaching hospitals with NICUsprimary

    Buy Neola® to pilot continuous lung monitoring and establish early clinical reference cases.

  • Children’s hospitalsprimary

    Purchase the system for high-acuity neonatal care and institutional research/education use.

  • General hospitals with neonatal intensive care unitssecondary

    Adopt the device for NICU monitoring where clinical and reimbursement fit is proven.

  • International NICUsemerging

    Potential future buyers after U.S. validation and European CE marking.

The company is headquartered in Lund, Sweden and also maintains a U.S. office in Palo Alto, California...

  • •Headquartered in Lund, Sweden
  • •U.S. office in Palo Alto, California
  • •Primary commercial focus is the United States
  • •Europe is a follow-on market after CE marking

Neola Medical’s strategy is to complete U.S. clinical studies, secure FDA market authorization, and then establish...

01
U.S. clinical validation and FDA approvalshort-term

Regulatory clearance is required before commercialization and market entry.

02
Pilot installations in reference NICUsshort-term

Early hospital references support adoption, reimbursement discussions, and distribution.

03
Reimbursement and pricing modelmedium-term

NICU adoption depends on payer acceptance and hospital economics.

04
European expansion after CE markingmedium-term

Broadens the addressable market once the product is validated and approved.

The business depends on successful clinical trials, regulatory approvals, and protection of intellectual property, all...

critical

Clinical trial and regulatory approval risk

Neola® must satisfy market-specific medical device requirements before launch.

Scope
U.S. FDA and later European CE processes
Materiality
high
high

Intellectual property risk

The company relies on patents and trade secrets to protect a novel medical device.

Scope
Patent grant, scope, and enforcement
Materiality
high
high

Financing risk

Development and clinical work consume cash before commercial revenue scales.

Scope
Equity funding and shareholder support
Materiality
high
high

Reimbursement and adoption risk

Hospitals may delay purchase if payer coverage or economic value is unclear.

Scope
U.S. NICU commercialization
Materiality
high
medium

Key personnel dependence

Specialist engineering, clinical, and regulatory expertise is concentrated in a small team.

Scope
Product development continuity
Materiality
medium
Fixed asset valuation
Could change reported asset values and impairment charges
Consolidation assessment
Affects group reporting scope and comparability
Warrants and dilution
Impacts EPS and ownership dilution

CalciMedica, Inc.

CALC · Pharmaceutical Preparations

Nu-Med Plus, Inc.

NUMD · Surgical & Medical Instruments & Apparatus

Neumora Therapeutics, Inc.

NMRA · Biological Products, (No Diagnostic Substances)

NEONC TECHNOLOGIES HOLDINGS, INC.

NTHI · Pharmaceutical Preparations

NeueHealth, Inc.

Hospital & Medical Service Plans

BeOne Medicines Ltd.

ONC · Pharmaceutical Preparations

: 11/08/2026